

IL6

Human-Mouse Chimeric anti-IL-6 (Siltuximab) mAb

Catalog No.	CSB110A CSB110B	Quantity:	200 µg 1.0 mg
Alternate Names:	CLLB8, CNTO 328, Sylvant		
Description:	Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.		
Concentration:	1.0 mg/ml		
UniProt ID (target):	P05231		
Source:	CHO cell line		
Isotype:	Human-mouse IgG1 kappa		
INN:	Siltuximab		
Specificity:	Human IL-6		
Biologic Activity:	IL-6 binding to receptor		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.